Literature DB >> 19685156

Effects of antifungal agents in sap activity of Candida albicans isolates.

Carolina Rodrigues Costa1, Rosália Santos Amorim Jesuíno, Janine de Aquino Lemos, Orionalda de Fátima Lisboa Fernandes, Lúcia Kioko Hasimoto e Souza, Xisto Sena Passos, Maria do Rosário Rodrigues Silva.   

Abstract

Some antifungal agents have shown to exert effects on expression of virulent factors of Candida as the production of secretory aspartyl proteinase (Sap). In this study, we sought to determine and to compare the influence of fluconazole and voriconazole in proteinase activity of this microorganism. Thirty-one isolates obtained from oral mucosa of human immunodeficiency virus positive (HIV) patients were used in this study. The minimal inhibitory concentrations (MIC) of fluconazole and voriconazole were determined using the broth microdilution method with RPMI 1640 medium and with yeast carbon base-bovine serum albumin (YCB-BSA) medium. The Sap activity following by digestion of BSA as substrate was determined for four Candida albicans strains arbitrarily chosen according to susceptibility (susceptible or resistant) to fluconazole or voriconazole. Besides, the SAP1 to SAP7 genes were screened by PCR for the same isolates that were determined by the Sap activity. In vitro susceptibility testing using the two media presented similar MIC values. Increased Sap activity was observed in resistant isolates on presence of drugs, but the Sap activity by susceptible isolates to azoles showed different behavior on the presence of drug. We detected the presence of SAP1 to SAP7 genes from all susceptible or resistant C. albicans isolates. The present study provides important data about the proteinase activity and the presence of genes of SAP family in fluconazole and voriconazole susceptible or resistant C. albicans isolates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19685156     DOI: 10.1007/s11046-009-9232-6

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  26 in total

1.  Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target.

Authors:  M Del Poeta; D L Toffaletti; T H Rude; C C Dykstra; J Heitman; J R Perfect
Journal:  Genetics       Date:  1999-05       Impact factor: 4.562

2.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

Review 3.  Antifungal agents--clinical pharmacokinetics and drug interactions.

Authors:  Hans-Peter Lipp
Journal:  Mycoses       Date:  2008       Impact factor: 4.377

4.  Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole.

Authors:  T Wu; K Wright; S F Hurst; C J Morrison
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 5.  Candida: a causative agent of an emerging infection.

Authors:  M A Ghannoum
Journal:  J Investig Dermatol Symp Proc       Date:  2001-12

Review 6.  Emerging fungal diseases.

Authors:  Marcio Nucci; Kieren A Marr
Journal:  Clin Infect Dis       Date:  2005-07-11       Impact factor: 9.079

7.  Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography.

Authors:  Yanjun Li; M Hong Nguyen; Hartmut Derendorf; Shaoji Cheng; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

Review 8.  Antifungal prophylaxis with azole derivatives.

Authors:  E Castagnola; M Machetti; B Bucci; C Viscoli
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

9.  Virulence factors and antifungal susceptibility of Candida albicans isolates from oral candidosis patients and control individuals.

Authors:  Cristiane Yumi Koga-Ito; Juliana Pereira Lyon; Valerio Vidotto; Maria Aparecida de Resende
Journal:  Mycopathologia       Date:  2006-04       Impact factor: 2.574

10.  Metabolic specialization associated with phenotypic switching in Candidaalbicans.

Authors:  Chung-Yu Lan; George Newport; Luis A Murillo; Ted Jones; Stewart Scherer; Ronald W Davis; Nina Agabian
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-23       Impact factor: 11.205

View more
  5 in total

1.  In vitro Candida albicans biofilm induced proteinase activity and SAP8 expression correlates with in vivo denture stomatitis severity.

Authors:  Gordon Ramage; Brent Coco; Leighann Sherry; Jeremy Bagg; David F Lappin
Journal:  Mycopathologia       Date:  2012-07       Impact factor: 2.574

2.  Anticandidal activity and biocompatibility of a rechargeable antifungal denture material.

Authors:  C C Villar; A L Lin; Z Cao; X-R Zhao; L-A Wu; S Chen; Y Sun; C-K Yeh
Journal:  Oral Dis       Date:  2012-09-07       Impact factor: 3.511

3.  Upregulation of secreted aspartyl proteinase genes of fluconazole-sensitive Candida albicans isolates.

Authors:  Carolina do Rosário Esteves Guimarães; Humberto Fonseca de Freitas; Tânia Fraga Barros
Journal:  Mol Biol Rep       Date:  2019-10-10       Impact factor: 2.316

Review 4.  The regulation of hyphae growth in Candida albicans.

Authors:  Hui Chen; Xuedong Zhou; Biao Ren; Lei Cheng
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

5.  Sub-MICs of Carum copticum and Thymus vulgaris influence virulence factors and biofilm formation in Candida spp.

Authors:  Mohd S A Khan; Iqbal Ahmad; Swaranjit S Cameotra; Francien Botha
Journal:  BMC Complement Altern Med       Date:  2014-09-15       Impact factor: 3.659

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.